Status:
COMPLETED
Gemini Symbicort pMDI
Lead Sponsor:
AstraZeneca
Conditions:
Mild or Moderate Asthma
Eligibility:
All Genders
12+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether treatment with Symbicort for 12 weeks will improve lung function and symptoms of adults and adolescents with asthma.
Eligibility Criteria
Inclusion
- Diagnosis of asthma
- Baseline lung function tests as determined by protocol.
- Required and received treatment with inhaled corticosteroids and/or lung treatments specified in the protocol within timeframe and doses specified in protocol.
Exclusion
- Severe asthma
- Has required treatment with any non-inhaled corticosteroid within previous 4 weeks, has sensitivity to drugs specified in the protocol or requires treatment with beta-blockers
- Had cancer within previous 5 years or currently has any other significant disease or disorder as judged by the investigator
Key Trial Info
Start Date :
October 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2005
Estimated Enrollment :
615 Patients enrolled
Trial Details
Trial ID
NCT00646516
Start Date
October 1 2003
End Date
February 1 2005
Last Update
January 24 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.